Form 4: Zevra Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
Neil F. Mcfarlane, President and CEO and a Director of Zevra Therapeutics, Inc., sold 20,000 shares of common stock on October 10, 2026 for $11.25 per share.
Summary
- Option exercise/conversion: acquired 50,000 Common Stock on October 10, 2026; holds 437,225 after (Direct).
- Open-market sale: disposed of 20,000 Common Stock at $11.25 ($224,948) on October 12, 2026; holds 417,225 after (Direct).
- Option exercise/conversion: disposed of 50,000 Restricted Stock Unit on October 10, 2026; holds 50,000 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $224,948 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Neil F. Mcfarlane — Director, Officer (President and CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-10 | Option exercise/conversion | Common Stock | 50,000 | — | — | 437,225 |
| 2026-10-12 | Open-market sale | Common Stock | 20,000 | $11 | $224.9K | 417,225 |
| 2026-10-10 | Option exercise/conversion | Restricted Stock Unit | 50,000 | — | — | 50,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-10 | Option exercise/conversion (50,000 shares) |
| 2026-10-12 | Open-market sale (20,000 shares) |
| 2026-10-10 | Option exercise/conversion (50,000 shares) |
Keywords
insider transaction, Form 4, ZVRA, ZEVRA THERAPEUTICS, INC., bearish, Neil F. Mcfarlane
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.